“Pediatric rare diseases are uniquely challenging because each one affects only a few children, but together they have severe consequences for millions worldwide. DiMe’s core set of digital measures establishes a shared language and framework for a range of conditions. This not only lets us speed up individual clinical trials, but also change how we measure progress in small patient groups, making sure every child’s data can help improve care for others.”

– Amy Molten | Chief Medical Officer, Ladder Health | Chair, Section on Advances in Therapeutics & Technology, American Academy of Pediatrics